Occasionally when I write a post there is an angry reaction to it in the blog comments, which was the case for my recent fact-check of the LifeWave X39 patches. As you can see in that post, I didn’t find convincing data to either back up the claimed stem cell connection. In my opinion, there […]
Weekly reads: bat stem cells & viruses, Lineage Cell, He Jiankui visa Read More »
The idea of mesenchymal cells or MSCs for MS has been around for a long time. However, there haven’t been that many strong clinical trials testing it. There’s a new paper out that reports one of the stronger MSC-related trials for MS in terms of design. In this case, they didn’t use just MSCs but
Mostly discouraging trial of MSC-NPs or purported neural cells from MSCs for MS Read More »
When I first saw the new FDA warning on stem cells for pets and the logo for the company that received it, I was surprised in a few ways. I don’t recall ever seeing such a letter and the logo is something else. We’ll get into all of that in a moment, but first, since
Recommended reads: FDA warning on stem cells for pets, chromatin, aging & HSCs Read More »
Last week one of the most popular stories was about a preprint from a mammoth de-extinction research group led by George Church having made elephant stem cells. I finally got a chance to look carefully at their preprint. Elephant stem cells preprint and mammoth de-extinction The elephant stem cells preprint has solid data. It looks like
Weekly reads: elephant stem cells, RIP Connie Eaves, AI cell biology Read More »
A reader of The Niche recently asked me, “What about stem cells for deafness?” It’s a great question and, as they pointed out, stem cells for vision loss gets much more attention. I’ve covered the translational progress of stem cells to treat many diseases but there has been less progress for deafness in the regenerative
Long-term hope on stem cells for deafness Read More »
Retraction Watch has been a great resource for those of us who have been following research misconduct. They widely cover and conduct research on retractions, corrections, and other developments in this space. Unfortunately, there’s been plenty to write about even just within the stem cell and cell therapy arena, which is my primary interest. Think
CRISPR gene editing has made rapid progress heading from bench to bedside. Perhaps the fastest has been its progress toward clinical use to combat sickle cell disease. We’ll start with a new paper on one major effort here. CRISPR gene editing. This process often involves cutting DNA, which then can be used as an opening to
Weekly reads: CRISPR sickle cell, Parkinson’s, pig-human chimera concerns Read More »
When people find out that I’m a stem cell researcher, a common question is whether there’s something they can take that is a stem cell activator. I’ve written before about whether there are stem cell boosts that one can do to try to be healthier. Sleep, stem cell activator and clonality Mostly when I bring
Weekly reads: stem cell activator, sleep & stem cells, clonal hematopoiesis Read More »
A quick review of the publicly-traded stem cell stocks I’ve been following in 2021 finds mostly discouraging news, but a few firms relatively outperformed the other publically-traded biotechs. One had some great news today. In this post, I’m doing a brief overview of how things went this year in the regenerative medicine space. I’m going
2021 scorecard for stem cell stocks: REGN, VCEL, CCEL, LCTX did best Read More »
I’d say the paper of the week is on how PRC2 mediated H3K27me3 can in some sense replace elements of DNA methylation to repress. Very cool. Here it is: Sex-specific chromatin remodelling safeguards transcription in germ cells, Nature. Weird stuff In a merger of opposites, City of Hope to buy Cancer Treatment Centers of America
Weekly reads: PRC2, 2 weird bits of news, pubs, COVID stem cell hype Read More »